Eisman J A, Suva L J, Frampton R J
Aust N Z J Surg. 1984 Feb;54(1):17-20.
Studies by this laboratory have demonstrated the presence of specific, high affinity 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) receptors both in surgical specimens of human breast cancer and in breast cancer cells in culture. We report here that 1,25-(OH)2D3 receptors were found in 54% of 230 human primary breast cancers. Although receptor levels are lower than those of oestrogen receptors, using a modified and more sensitive assay method, the apparent receptor concentration is increased without altering the receptor positivity rate. Also in preliminary studies on lymph node metastases and their primary tumours, the receptor positivity rate is higher in the lymph nodes. These findings suggest that metastatic cells may be selected for the presence of 1,25-(OH)2D3 receptors. These data, taken with the evidence that 1,25-(OH)2D3 and several of its metabolites inhibit the growth of human breast cancer cells in culture, exactly analogously with the effects of oestrogens on cancer cell growth in vitro and in vivo, indicate that 1,25-(OH)2D3 or its metabolites could have a role in the 'hormonal' therapy of metastatic human breast cancer.
本实验室的研究已证实在人乳腺癌手术标本以及培养的乳腺癌细胞中均存在特异性、高亲和力的1,25 - 二羟维生素D3（1,25-(OH)2D3）受体。我们在此报告，在230例人原发性乳腺癌中，54%发现有1,25-(OH)2D3受体。尽管受体水平低于雌激素受体，但采用改良的更敏感检测方法时，表观受体浓度增加而不改变受体阳性率。同样，在对淋巴结转移灶及其原发肿瘤的初步研究中，淋巴结中的受体阳性率更高。这些发现提示转移细胞可能因存在1,25-(OH)2D3受体而被选择。这些数据，结合1,25-(OH)2D3及其几种代谢产物抑制培养的人乳腺癌细胞生长的证据，这与雌激素在体外和体内对癌细胞生长的作用完全类似，表明1,25-(OH)2D3或其代谢产物可能在转移性人乳腺癌的“激素”治疗中发挥作用。
